MarÃ-a Luisa Lozano

List of Publications by Year
in descending order

146	3,391	172457	175258
papers	citations	29 h-index	52 g-index

159	159	159	4732
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	New developments in the diagnosis of primary immune thrombocytopenia. Blood Coagulation and Fibrinolysis, 2022, 33, S5-S7.	1.0	2
2	Thrombopoietin receptor agonist in chemotherapy-induced thrombocytopenia. Lancet Haematology,the, 2022, 9, e168-e169.	4.6	6
3	Src-related thrombocytopenia: a fine line between a megakaryocyte dysfunction and an immune-mediated disease. Blood Advances, 2022, 6, 5244-5255.	5.2	3
4	Registries in immune thrombocytopenia (ITP) in Europe: the European Research Consortium on ITP (<scp>ERCI</scp>) network. British Journal of Haematology, 2022, 197, 633-638.	2.5	2
5	Two SERPINC1 variants affecting N-glycosylation of Asn224 cause severe thrombophilia not detected by functional assays. Blood, 2022, 140, 140-151.	1.4	11
6	Implication of Hepsin from Primary Tumor in the Prognosis of Colorectal Cancer Patients. Cancers, 2022, 14, 3106.	3.7	6
7	A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients. Blood Cells, Molecules, and Diseases, 2021, 86, 102505.	1.4	4
8	Neutrophil extracellular traps and von Willebrand factor are allies that negatively influence COVIDâ€19 outcomes. Clinical and Translational Medicine, 2021, 11, e268.	4.0	15
9	A pilot study on the impact of congenital thrombophilia in COVIDâ€19. European Journal of Clinical Investigation, 2021, 51, e13546.	3.4	16
10	Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia. International Journal of Molecular Sciences, 2021, 22, 4330.	4.1	12
11	Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Scientific Reports, 2021, 11, 7792.	3.3	28
12	Inherited Platelet Disorders: An Updated Overview. International Journal of Molecular Sciences, 2021, 22, 4521.	4.1	44
13	Elucidating the Mechanism of Action of the Attributed Immunomodulatory Role of Eltrombopag in Primary Immune Thrombocytopenia: An In Silico Approach. International Journal of Molecular Sciences, 2021, 22, 6907.	4.1	10
14	Recomendaciones del Grupo EspaÃ±ol de PTI para el diagnÃ³stico, tratamiento y seguimiento de pacientes con trombocitopenia inmune. Medicina ClÃnica, 2021, 157, 191-198.	0.6	10
15	Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombocytopenia. Medicina ClÃnica (English Edition), 2021, 157, 191-198.	0.2	0
16	Expanding the genetic spectrum of TUBB1-related thrombocytopenia. Blood Advances, 2021, 5, 5453-5467.	5.2	12
17	A novel genetic variant in <scp>PTGS1</scp> affects Nâ€glycosylation of cyclooxygenaseâ€1 causing a dominantâ€negative effect on platelet function and bleeding diathesis. American Journal of Hematology, 2021, 96, E83-E88.	4.1	2
18	Respuesta. Medicina ClÃnica, 2021, 158, e2-e2.	0.6	0

#	Article	IF	Citations
19	Circulating microRNAs in patients with immune thrombocytopenia before and after treatment with thrombopoietin-receptor agonists. Platelets, 2020, 31, 198-205.	2.3	19
20	Retrospective Multicenter Study of Extracorporeal Photopheresis in Steroid-Refractory Acute and Chronic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2020, 26, 651-658.	2.0	18
21	Markers of endothelial cell activation and neutrophil extracellular traps are elevated in immune thrombocytopenia but are not enhanced by thrombopoietin receptor agonists. Thrombosis Research, 2020, 185, 119-124.	1.7	20
22	Platelet activation and neutrophil extracellular trap (NET) formation in immune thrombocytopenia: is there an association?. Platelets, 2020, 31, 906-912.	2.3	8
23	Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia. Expert Review of Hematology, 2020, 13, 1319-1332.	2.2	10
24	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	3.5	7
25	Avatrombopag for the management of thrombocytopenia in patients with chronic liver disease. Revista Espanola De Enfermedades Digestivas, 2020, 113, 136-140.	0.3	0
26	MicroRNAs as potential regulators of platelet function and bleeding diatheses. Platelets, 2019, 30, 803-808.	2.3	14
27	Management of Adult Patients with Primary Immune Thrombocytopenia (ITP) in Clinical Practice: A Consensus Approach of the Spanish ITP Expert Group. Advances in Hematology, 2019, 2019, 1-11.	1.0	2
28	GENYOi005-A: An induced pluripotent stem cells (iPSCs) line generated from a patient with Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM) carrying a p.Thr196Ala variant. Stem Cell Research, 2019, 41, 101603.	0.7	4
29	Identification of novel variants in ten patients with Hermansky-Pudlak syndrome by high-throughput sequencing. Annals of Medicine, 2019, 51, 141-148.	3.8	11
30	Molecular Diagnosis of Inherited Coagulation and Bleeding Disorders. Seminars in Thrombosis and Hemostasis, 2019, 45, 695-707.	2.7	32
31	RASGRP2 gene variations associated with platelet dysfunction and bleeding. Platelets, 2019, 30, 535-539.	2.3	12
32	Prospective multi-center national study to standardize the follow-up of type 1 Gaucher disease patients treated with eliglustat under standard of care practice: TRAZELGA project. Molecular Genetics and Metabolism, 2019, 126, S22-S23.	1.1	0
33	Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Scientific Reports, 2019, 9, 16680.	3.3	15
34	Impaired hemostatic activity of healthy transfused platelets in inherited and acquired platelet disorders: Mechanisms and implications. Science Translational Medicine, 2019, 11, .	12.4	14
35	Multirefractory primary immune thrombocytopenia; targeting the decreased sialic acid content. Platelets, 2019, 30, 743-751.	2.3	45
36	Do Guidelines Influence Diagnostic and Therapeutic Practice in Immune Thrombocytopenia? Results of a Multicenter Retrospective Study. Blood, 2019, 134, 1088-1088.	1.4	1

#	Article	IF	Citations
37	Predictive Factors for Thrombopoietin Receptor Agonist Free Responses in Chronic ITP Patients: A Multicenter Retrospective Study with Long-Term Follow-up. Blood, 2019, 134, 2370-2370.	1.4	1
38	Strategies for Analysis of Novel Molecular Variants in the RUNX1 Gene As a Cause of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML). Blood, 2019, 134, 2359-2359.	1.4	0
39	Influence of Age on Treatment with Thrombopoietin Receptor Agonists in Patients with Immune Thrombocytopenia; A Retrospective Multicenter Study. Blood, 2019, 134, 2361-2361.	1.4	8
40	A New Molecular Variant in the PTGS1 Gene That Abrogates Generation of Thromboxane A2 Synthesis and Associates with Platelet Dysfunction and Bleeding. Blood, 2019, 134, 2375-2375.	1.4	0
41	Identification of Circulating microRNA Signatures As Potential Noninvasive Biomarkers for Prediction to Response to Extracorporeal Photoapheresis in Patients with Graft Versus Host Disease. Blood, 2019, 134, 4466-4466.	1.4	5
42	Significant Hypo-Responsiveness to GPVI and CLEC-2 Agonists in Pre-Term and Full-Term Neonatal Platelets and following Immune Thrombocytopenia. Thrombosis and Haemostasis, 2018, 118, 1009-1020.	3.4	29
43	Comparative assessment of prophylactic transfusions of platelet concentrates obtained by the PRP or buffy-coat methods, in patients undergoing allogeneic hematopoietic stem cell transplantation. Hematology, 2018, 23, 712-718.	1.5	0
44	Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders. Haematologica, 2018, 103, 148-162.	3.5	96
45	Identification of two novel mutations in RASGRP2 affecting platelet CalDAG-GEFI expression and function in patients with bleeding diathesis. Platelets, 2018, 29, 192-195.	2.3	26
46	A Modern Approach to the Molecular Diagnosis of Inherited Bleeding Disorders. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2018, 12, .	0.1	2
47	An early increase of CD56^{bright} natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graftâ€versusâ€host disease. Transfusion, 2018, 58, 2924-2932.	1.6	20
48	Phenotype description and response to thrombopoietin receptor agonist in DIAPH1-related disorder. Blood Advances, 2018, 2, 2341-2346.	5.2	33
49	Performance and usefulness of platelet aggregation testing. Platelets, 2018, 29, 637-637.	2.3	1
50	Multicentric, Retrospective Study of Extracorporeal Photopheresis, Off-Line System, in Corticosteroid Refractory Acute and Chronic Graft-Versus-Host Disease. Blood, 2018, 132, 3405-3405.	1.4	0
51	Ten New Cases of Hermansky-Pudlak Syndrome in the Iberian Peninsula: Identification of Novel Genetic Variants in HPS3, HPS4, HPS6 and DTNBP1 Associated with Significant Clinical Complications. Blood, 2018, 132, 1147-1147.	1.4	0
52	Prospective National-Base Multicenter Study to Standardize the Follow-up of Type 1Gaucher Disease Patients Treated with Eliglustat Under Standard of Care Practice. Trazelga Project. Blood, 2018, 132, 4942-4942.	1.4	0
53	Quality assessment and transfusion efficacy of buffy coat-derived platelet concentrates washed with platelet additive solution. Blood Transfusion, 2018, 16, 273-278.	0.4	2
54	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92

#	Article	IF	Citations
55	Induced pluripotent stem cells derived from Bernard-Soulier Syndrome patient's peripheral blood cells with a p.Phe55Ser mutation in the GPIX gene. Stem Cell Research, 2017, 20, 10-13.	0.7	1
56	Transient desialylation in combination with a novel antithrombin deficiency causing a severe and recurrent thrombosis despite anticoagulation therapy. Scientific Reports, 2017, 7, 44556.	3.3	4
57	Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia. Journal of Thrombosis and Haemostasis, 2017, 15, 1859-1866.	3.8	34
58	Biallelic Mutations in KDSR Disrupt Ceramide Synthesis and Result in aÂSpectrum of Keratinization Disorders Associated with Thrombocytopenia. Journal of Investigative Dermatology, 2017, 137, 2344-2353.	0.7	53
59	Wiskottâ€“Aldrich syndrome in a child presenting with macrothrombocytopenia. Platelets, 2017, 28, 417-420.	2.3	19
60	Down Regulation of the Munc18b-syntaxin-11 Complex and Î²1-tubulin Impairs Secretion and Spreading in Neonatal Platelets. Thrombosis and Haemostasis, 2017, 117, 2079-2091.	3.4	19
61	Allogeneic hematopoietic cell transplantation in an adult patient with Glanzmann thrombasthenia. Clinical Case Reports (discontinued), 2017, 5, 1887-1890.	0.5	6
62	Resistin in morbidly obese patients before and after gastric bypass surgery. Nutricion Hospitalaria, 2017, 34, 1333-1337.	0.3	10
63	Thrombopoietin receptor agonists in conjunction with oseltamivir for immune thrombocytopenia. Aids, 2016, 30, 1141-1142.	2.2	7
64	Design and application of a 23â€gene panel by nextâ€generation sequencing for inherited coagulation bleeding disorders. Haemophilia, 2016, 22, 590-597.	2.1	43
65	Persistent cytotoxic T lymphocyte expansions after allogeneic haematopoietic stem cell transplantation: kinetics, clinical impact and absence of <scp>STAT</scp>3 mutations. British Journal of Haematology, 2016, 172, 937-946.	2.5	16
66	Generation of a human induced pluripotent stem cell (iPSC) line from a Bernard-Soulier syndrome patient with the mutation p.Asn45Ser in the GPIX gene. Stem Cell Research, 2016, 17, 603-606.	0.7	2
67	Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Annals of Hematology, 2016, 95, 1089-1098.	1.8	23
68	Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction. Blood, 2016, 128, 1282-1289.	1.4	68
69	Generation of induced pluripotent stem cells (iPSCs) from a Bernardâ€“Soulier syndrome patient carrying a W71R mutation in the GPIX gene. Stem Cell Research, 2016, 16, 692-695.	0.7	8
70	Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. British Journal of Haematology, 2016, 172, 813-815.	2.5	19
71	Obesity, endothelial function and inflammation: the effects of weight loss after bariatric surgery. Nutricion Hospitalaria, 2016, 33, 1340-1346.	0.3	18
72	Evaluation of Novel Platelet Polymorphisms in Stroke. Dichotomic Effect of rs5443 inGNB3.		

#	Article	IF	Citations
73	An atypical IgM class platelet cold agglutinin induces GPVI-dependent aggregation of human platelets. Thrombosis and Haemostasis, 2015, 114, 313-324.	3.4	5
74	Persistent Cytotoxic T Lymphocyte Expansions after Allogeneic Hematopoietic Stem Cell Transplantation: Kinetics, Clinical Impact and Absence of STAT3 Mutations. Blood, 2015, 126, 3153-3153.	1.4	0
75	Hermansky-Pudlak syndrome. Hamostaseologie, 2014, 34, 301-309.	1.9	26
76	Functional and molecular characterization of inherited platelet disorders in the Iberian Peninsula: results from a collaborative study. Orphanet Journal of Rare Diseases, 2014, 9, 213.	2.7	29
77	Chediakâ€“<scp>H</scp>igashi syndrome: description of two novel homozygous missense mutations causing divergent clinical phenotype. European Journal of Haematology, 2014, 92, 49-58.	2.2	23
78	Quality assessment of buffyâ€coatâ€derived leucodepleted platelet concentrates in <scp>PAS</scp>â€plasma, prepared by the <scp>O</scp>rbi<scp>S</scp>ac or <scp>TACSI</scp> automated system. Vox Sanguinis, 2014, 106, 38-44.	1.5	9
79	High on-treatment platelet reactivity in patients with ischemic cerebrovascular disease. Blood Coagulation and Fibrinolysis, 2014, 25, 604-611.	1.0	19
80	Evaluation of twoâ€step haemoglobin screening with HemoCue for blood donor qualification in mobile collection sites. Vox Sanguinis, 2014, 107, 343-350.	1.5	3
81	Towards the targeted management of Chediak-Higashi syndrome. Orphanet Journal of Rare Diseases, 2014, 9, 132.	2.7	57
82	Proteomic analysis of platelet N-glycoproteins in PMM2-CDG patients. Thrombosis Research, 2014, 133, 412-417.	1.7	15
83	Design and Validate of Next-Generation Sequencing Panel for Inherited Platelet Disorders. Blood, 2014, 124, 4210-4210.	1.4	2
84	Deubiquitnase BAP1 Downregulation in Myeloid Malignances: A New Pathogenic Mechanism, Dominant in Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 5594-5594.	1.4	0
85	GPI-anchor and GPI-anchored protein expression in PMM2-CDG patients. Orphanet Journal of Rare Diseases, 2013, 8, 170.	2.7	13
86	Hematologic Î²-Tubulin VI Isoform Exhibits Genetic Variability That Influences Paclitaxel Toxicity. Cancer Research, 2012, 72, 4744-4752.	0.9	26
87	Influence of CYP2C19 Polymorphisms in Platelet Reactivity and Prognosis in an Unselected Population of Non ST Elevation Acute Coronary Syndrome. Revista Espanola De Cardiologia (English Ed), 2012, 65, 219-226.	0.6	6
88	Influencia de los polimorfismos de CYP2C19 en la reactividad plaquetaria y el pronÃ³stico en una poblaciÃ³n no seleccionada de pacientes con sÃndrome coronario agudo sin elevaciÃ³n del ST. Revista Espanola De Cardiologia, 2012, 65, 219-226.	1.2	16
89	An innovative flow cytometric approach for small-size platelet microparticles: Influence of calcium. Thrombosis and Haemostasis, 2012, 108, 373-383.	3.4	31
90	Obesity and Inflammation: Change in Adiponectin, C-Reactive Protein, Tumour Necrosis Factor-Alpha and Interleukin-6 After Bariatric Surgery. Obesity Surgery, 2012, 22, 950-955.	2.1	207

#	Article	IF	Citations
91	Evaluation of platelet function during extended storage in additive solution, prepared in a new container that allows manual buffy-coat platelet pooling and leucoreduction in the same system. Blood Transfusion, 2012, 10, 480-9.	0.4	15
92	Rare homozygous status of P43 Î²1-tubulin polymorphism causes alterations in platelet ultrastructure. Thrombosis and Haemostasis, 2011, 105, 855-863.	3.4	19
93	Impact of Constitutional Polymorphisms in VCAM1, CD44, CXCL12, CXCR4 and CSF3R in Progenitor Cell Mobilization in Patients with Hematological Malignancies. Blood, 2011, 118, 2997-2997.	1.4	0
94	Effect of quercetin on platelet spreading on collagen and fibrinogen and on multiple platelet kinases. FÃ¬toterapÃ¬Ã¢, 2010, 81, 75-80.	2.2	28
95	Does the Holy Grail escape us again?. European Heart Journal, 2009, 30, 1152-1152.	2.2	0
96	Platelet receptors and signaling in the dynamics of thrombus formation. Haematologica, 2009, 94, 700-711.	3.5	337
97	CCR6 regulates EAE pathogenesis by controlling regulatory CD4⁺ Tâ€cell recruitment to target tissues. European Journal of Immunology, 2009, 39, 1671-1681.	2.9	114
98	Genotypeâ€“phenotype relationship for six common polymorphisms in genes affecting platelet function from 286 healthy subjects and 160 patients with mucocutaneous bleeding of unknown cause. British Journal of Haematology, 2009, 146, 95-103.	2.5	16
99	Differential effects of quercetin, apigenin and genistein on signalling pathways of proteaseâ€activated receptors PAR₁ and PAR₄ in platelets. British Journal of Pharmacology, 2009, 158, 1548-1556.	5.4	44
100	IgM monoclonal component associated with type I Gaucher disease resolved after enzyme replacement therapy: A case report. Journal of Inherited Metabolic Disease, 2009, 32, 265-267.	3.6	10
101	Thromboxane A₂Receptor Antagonism by Flavonoids: Structureâ^'Activity Relationships. Journal of Agricultural and Food Chemistry, 2009, 57, 1589-1594.	5.2	46
102	ABO blood group does not increase the risk of thrombosis in Philadelphia-negative myeloproliferative disorders. Blood Coagulation and Fibrinolysis, 2009, 20, 390-392.	1.0	1
103	JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia. Annals of Hematology, 2008, 87, 763-765.	1.8	11
104	Apigenin Inhibits Platelet Adhesion and Thrombus Formation and Synergizes with Aspirin in the Suppression of the Arachidonic Acid Pathway. Journal of Agricultural and Food Chemistry, 2008, 56, 2970-2976.	5.2	74
105	Successful mobilization of hematopoietic peripheral blood progenitor cells with paclitaxel-based chemotherapy as initial or salvage regimen in patients with hematologic malignancies. Haematologica, 2008, 93, 1436-1438.	3.5	4
106	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. Thrombosis and Haemostasis, 2008, 100, 1211-1213.	3.4	6
107	TUBB1 Q43P polymorphism does not protect against acute coronary syndrome and premature myocardial infarction. Thrombosis and Haemostasis, 2008, 100, 1211-3.	3.4	4
108	The association of the Â1-tubulin Q43P polymorphism with intracerebral hemorrhage in men. Haematologica, 2007, 92, 513-518.	3.5	38

#	Article	IF	Citations
109	Evaluation of four rapid methods for hemoglobin screening of whole blood donors in mobile collection settings. Transfusion and Apheresis Science, 2007, 36, 235-242.	1.0	46
110	Flavonoids inhibit the platelet TxA2signalling pathway and antagonize TxA2receptors (TP) in platelets and smooth muscle cells. British Journal of Clinical Pharmacology, 2007, 64, 133-144.	2.4	76
111	Latent and polymeric antithrombin: clearance and potential thrombotic risk. Experimental Biology and Medicine, 2007, 232, 219-26.	2.4	11
112	CCR6 regulates the function of alloreactive and regulatory CD4+T cells during acute graft-versus-host disease. Leukemia and Lymphoma, 2006, 47, 1469-1476.	1.3	22
113	Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. Journal of Thrombosis and Haemostasis, 2005, 3, 369-376.	3.8	168
114	Evaluation of refrigerated platelet concentrates supplemented with low doses of second messenger effectors. International Journal of Laboratory Hematology, 2004, 26, 275-286.	0.2	7
115	Detection of free hepatitis C virus core antigen by enzyme-linked immunosorbent assay is not suitable for screening of granulocyte colony-stimulating factor-mobilized hematopoietic progenitor donors. Transfusion, 2004, 44, 1755-1761.	1.6	0
116	In Vitro Changes of Platelet Parameters: Lessons From Blood Banking. , 2004, 273, 057-072.		8
117	Efecto de la administraciÃ³n precoz de pravastatina en los valores de proteÃna C reactiva y de interleucina 6 en la fase aguda del infarto de miocardio con elevaciÃ³n del segmento ST. Revista Espanola De Cardiologia, 2004, 57, 916-923.	1.2	5
118	Trasplante de progenitores hematopoyÃ©ticos de sangre perifÃ©rica en EspaÃ±a: anÃ¡lisis de coste. Medicina ClÃnica, 2004, 123, 401-405.	0.6	1
119	Evaluation of a new whole-blood filter that allows preparation of platelet concentrates by platelet-rich plasma methods. Transfusion, 2003, 43, 1723-1728.	1.6	11
120	Application of a new enzyme-linked immunosorbent assay for detection of total hepatitis C virus core antigen in blood donors. Transfusion Medicine, 2003, 13, 259-266.	1.1	25
121	The â^'1C>T mutation in the annexin A5gene does not affect plasma levels of annexin A5. Blood, 2003, 101, 4223-4224.	1.4	12
122	Platelet aggregation through prothrombinase activation induced by non-aggregant doses of platelet agonists. Blood Coagulation and Fibrinolysis, 2002, 13, 95-103.	1.0	3
123	A common polymorphism in the annexin V Kozak sequence (-1C>T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients. Blood, 2002, 100, 2081-6.	1.4	11
124	Administration of post-autologous PBSCT rhG-CSF is associated with long-term low concentrations of bone marrow hematopoietic progenitor cells. Bone Marrow Transplantation, 2001, 27, 1287-1292.	2.4	11
125	Polymorphisms of P-selectin glycoprotein ligand-1 are associated with neutrophil-platelet adhesion and with ischaemic cerebrovascular disease. British Journal of Haematology, 2001, 115, 969-976.	2.5	38
126	Evaluation of pooled platelet concentrates using prestorage versus poststorage WBC reduction: impact of filtration timing. Transfusion, 2000, 40, 781-788.	1.6	23

#	Article	IF	Citations
127	Re-mobilization of peripheral blood progenitor cells within a short time interval fails to achieve effective progenitor cell yields. Bone Marrow Transplantation, 2000, 26, 351-352.	2.4	1
128	Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Bone Marrow Transplantation, 2000, 25, 231-235.	2.4	9
129	In vitro analysis of platelet concentrates stored in the presence of modulators of 3â€²,5â€² adenosine monophosphate, and organic anions. Transfusion Science, 2000, 22, 3-11.	0.6	4
130	Complejo plaquetario GP Ib/IX/V: papel fisiolÃ³gico. Journal of Physiology and Biochemistry, 2000, 56, 355-365.	3.0	10
131	The TFPI 536C â†’T Mutation Is not Associated with Increased Risk for Venous or Arterial Thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-788.	3.4	30
132	The TFPI 536C-->T mutation is not associated with increased risk for venous or arterial thrombosis. Thrombosis and Haemostasis, 2000, 83, 787-8.	3.4	3
133	Quality assessment of platelet concentrates supplemented with second-messenger effectors. Transfusion, 1999, 39, 135-143.	1.6	28
134	Platelet Cryopreservation Using a Reduced Dimethyl Sulfoxide Concentration and Second-Messenger Effectors as Cryopreserving Solution. Cryobiology, 1999, 39, 1-12.	0.7	17
135	Bone marrow steady-state CD34+/CD71âˆ’ cell content is a predictive value of rG-CSF-mobilized CD34+ cells. Bone Marrow Transplantation, 1998, 21, 983-985.	2.4	4
136	A Radioreceptor Assay for Mass Measurement of Inositol (1,4,5)-Trisphosphate Using Saponin-Permeabilized Outdated Human Platelets. Analytical Biochemistry, 1998, 256, 117-121.	2.4	2
137	New alleles of the platelet glycoprotein IbÎ± gene. British Journal of Haematology, 1998, 103, 997-1003.	2.5	22
138	Migraine and prothrombotic genetic risk factors. Cephalalgia, 1998, 18, 257-260.	3.9	32
139	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	168
140	Polymorphisms of Platelet Membrane Glycoprotein Ibîœ€ Associated With Arterial Thrombotic Disease. Blood, 1998, 92, 2771-2776.	1.4	4
141	Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease. Blood, 1998, 92, 2771-6.	1.4	30
142	The venous thrombosis risk factor 20210 A allele of the prothrombin gene is not a major risk factor for arterial thrombotic disease. British Journal of Haematology, 1997, 99, 304-307.	2.5	92
143	Prospective Randomized Study Comparing the Efficacy of Bioequivalent Doses of glycosylated and nonglycosylated rG-CSF for Mobilizing Peripheral Blood Progenitor Cells. British Journal of Haematology, 1997, 96, 418-420.	2.5	34
144	Comparative Study of Three Methods to Detect Free Plasma Antiplatelet Antibodies. Acta Haematologica, 1996, 96, 135-139.	1.4	5

#	Article	IF	Citations
145	Immune recovery after autologous or rhGâ€CSF primed PBSC transplantation. European Journal of Haematology, 1996, 56, 301-307.	2.2	25
146	Effect of rhG-CSF on the mobilization of CD38 and HLA-DR subfractions of CD34+ peripheral blood progenitor cells. Annals of Hematology, 1995, 71, 105-110.	1.8	8